# Overcoming Drug Resistance in Multiple Myeloma

> **NIH NIH U54** · MAYO CLINIC ARIZONA · 2021 · $83,332

## Abstract

This supplement will allow the Mayo Clinic/University of Minnesota Myeloma DRSC to provide unique
resources and support to Dr. Constantine Mitsiades’ supplement to his U01. Dr. Mitsiades is studying the role
of glycosylation in drug resistance and in collaboration with the DRSC will analyze myeloma cell lines and drug
refractor patient samples for alterations in glycosylation. In addition, the DRSC will provide a unique animal
model of myeloma that will be used for in vivo selection of CRISPR targets that mediate drug resistance to
immunomodulatory drugs, proteasome inhibitors and T-cell engagers.

## Key facts

- **NIH application ID:** 10414667
- **Project number:** 3U54CA224018-04S1
- **Recipient organization:** MAYO CLINIC ARIZONA
- **Principal Investigator:** Peter Leif Bergsagel
- **Activity code:** U54 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $83,332
- **Award type:** 3
- **Project period:** 2017-09-01 → 2023-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10414667

## Citation

> US National Institutes of Health, RePORTER application 10414667, Overcoming Drug Resistance in Multiple Myeloma (3U54CA224018-04S1). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10414667. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*